- 8 health system, hospital CMO and CNO exits in 2026
- 10 new medical schools announced in 2026
- Physician-owned assisted living facility opens in Utah
- Leadership in the Age of Learning
- A genomics library for the AI era
- BMS bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nod
- My Husband Was Kicked Out of Hospice for Dying Too Slowly
- Trump Team’s Use of Arcane Budget Rule Threatens Medicaid Coverage
- Massachusetts moves to restrict kratom sales
- 1 dead in officer-involved shooting at Alabama hospital campus
- Cyclosporiasis admissions top 700: 4 things to know
- The value of ‘prosocial grand ambition’
- Meet the leaders of the fastest-growing dental practices
- WISeR’s high-stakes first year, in 8 questions
- Health system CEO pay in 2026: 6 trends to know
- 10 states with the biggest population gains and losses
- Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve
- Will cardiology’s ASC strategy pay off? CVL’s new CEO is betting on it
- 5 numbers making dentists optimistic
- 25 state behavioral health policy updates
- Wisconsin woman accused of posing as fake dentist ordered to pay customer $144K
- Physician independence is making a comeback — why ASCs are leading the way
- Surgery Partners is betting on physician recruiting, not M&A, for growth: 5 things to know
- Dentists battle insurance woes: 5 updates
- Philadelphia dentist dies at 86
- 4 injured after car crashes into North Carolina pediatric dental office
- Ellis Hospital sues St. Peter’s over cardiologist noncompetes, warns of $75M revenue risk
- Mental healthcare provider gaps, by state
- Park Dental Partners posts $66.2M in Q2 revenue
- 28 new behavioral health study findings to know
- 23 new behavioral health projects to know
- Which services are hit hardest by CON?
- 5 gastroenterologists in the headlines
- Where spine, orthopedic ASCs are gaining ground
- Aspen Dental continues 2026 growth with new Chicago practice
- Major PBMs agree to offer TrumpRx pricing information to members
- Distalmotion gets FDA clearance for hernia repair system
- NYC Health + Hospitals adds $600K ophthalmology microscope
- Providence reports $400M operating improvement halfway through 2026
- A look at where Aetna is seeing value-based care success in Medicare Advantage
- Nationwide program to quit smoking would save US $12B: Study
- Rare Bacteria In Coastal Waters Has Killed 7 This Summer
- Angelalign to appeal court’s decision in clear aligner patent infringement case
- It's crunch time for Karyopharm as company faces potential default next month
- UNC Health Pardee completes 23-bed behavioral health center
- Oregon State Hospital superintendent out after less than a month
- Nebraska ASC inks prime vendor agreement with Medline
- Affordable Care completes recapitalization, enters ‘next chapter’ of growth
- March of Dimes: Maternity care deserts persist, Medicaid cuts threaten to curb access further
- Trump administration refers scores of providers, pharmacies, PBMs to DOJ, OIG over past billing for pediatric gender-affirming care
- Socializing: A Prescription For Healthier Brain Aging
- Taking The Stairs May Lower Your Risk Of Dying From Heart Disease
- Obesity not a 'zero-sum game' as patients crave optionality, Novo CEO says: Reuters
- AZ's blood pressure newcomer Baxfendy fails to meet cost-effectiveness bar, ICER says
- Sweet Tooth? It Could Be Shaping Your Decisions, Study Says
- Stressed Parents Turn To Screens For Help, Study Finds
- Gambling Linked To Mental Health Problems Among College Students
- Hospitals Say They Found A Tool To Help Reduce Childbirth Risks: Wristbands
- Listen to the Latest ‘KFF Health News Minute’
- People With Disabilities Say Medicaid’s Limits on Income Stifle Career Advancement
- Readers Speak Out on Work Requirements, Federal Data Grab, Opioid Payback Cash
- Abbott to pump up blood supply with $1M college sports prize amid US crisis
- Federal agencies release ‘Treatment First’ toolkit
- California moves 15 behavioral health projects forward
- Neurocrine stands by blockbuster hopeful Vykat XR as Prader-Willi docs raise potential safety flags
- Appeals court tosses methodology for calculating NSA qualifying payment amounts
- UC San Diego Health, West Health launch $40M accelerator for 'tech-forward' coordinated care
- Epic releases Care Everywhere diagnostic image exchange to tackle healthcare's 'CD problem'
- FDA Wants More Information From Food Makers On New Food Chemicals
- Cityblock unveils partnership with Humana in North Carolina
- Antelope Recovery, offering SUD care for teens, to expand Spanish services in Colorado
- Legend interim CEO talks rising competition as Carvykti maker posts first profit
- Aspirin/Omega-3 Combo Matches Antibiotics In Treating Gum Disease, Trial Finds
- Endometriosis Linked To Higher Type 2 Diabetes Risk
- Cedar launches Kora Platform to build out agentic AI for medical billing
- Sharp HealthCare announces another reorganization affecting 260 workers
- Alfasigma gains arthritis drug, access to new markets with M&A play
- Common Health Coalition secures $100M from OpenAI Foundation to boost hepatitis C cure rates
- Lilly takes 6 companies to court for selling retatrutide knockoffs
- Tamiflu Helps Keep Severely Ill Kids Out Of The ICU, Study Finds
- 'Normal' Can Backfire During Doctor/Patient Discussions
- Experimental Pulse Oximeter Accurate Regardless Of Skin Tone, Researchers Say
- Suvi Health launches ambient AI solution for patients to reduce hospital stays and support care transitions
- The biggest payer and provider trends from Q2
- Patients Wary Of Governments, Companies Pushing AI As A Rural Healthcare Solution
- Hospitals Say They Found a Tool To Help Reduce Childbirth Risks: Wristbands
- Years After He Quit Smoking, a Lung Cancer Scan Saved His Life
- Hospital Prepayment Requirements Add New Wrinkles to Patients’ Financial Responsibility
- Fresenius pulls one batch of Actemra biosim over glass particle concerns
- Oracle Health debuts revamped patient portal with an AI upgrade
- Snapchat creates ad format to support pharma disclosure needs
- CMS ends Medicaid, CHIP funding for gender-affirming care for minors
- Healthcare CFOs face growing decision-making expectations. Many say they aren't ready
- Assort Health rolls out AI agent to automate referrals for specialty practices and health systems
- Claims data transparency empowers employers to act on affordability: survey
- Hims & Hers posts $753M in Q2 revenue as it preps for push into peptide market
- Executive Order Calls For Fewer Routine Childhood Vaccines, Doctors Push Back
- Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas
- Real-World Performance Of Alzheimer's Drug, Leqembi, Matches Trial Data, Study Finds
- Study Finds Undisclosed Chemicals In Most Personal Care Products
- Senators introduce bipartisan legislation to further antimicrobial resistance research
- CMS' mandatory VBC programs brought substantial administrative costs for hospitals: study
- Flagler Health secures $50M series B for AI-native MSK care platform expansion
- Attruby cruises toward blockbuster land as BridgeBio CEO spots ‘stabilizer-first’ ATTR market
- WuXi AppTec scores temporary win amid fight over DOD's Chinese military company brand
- Barbie And Ken Fade From Fantasy, Offer More Realistic Proportions, Study Finds
- Children Should Get Flu Vaccine, Top Pediatrics Group Recommends
- Together, Two Everyday Health Factors Double Death Risk In Midlife And Beyond
- Many States Cover Doula Care, But Access To A 'Birthing Bestie' Is Often Out Of Reach
- Patients Wary of Governments, Companies Pushing AI as a Rural Healthcare Solution
- A Federal Policy Is Complicating How Organizations Battle the Opioid Crisis
- Chairman Paul S. Atkins Letter to Robert Walley, Chair, CAT NMS Plan Operating Committee
- Trump signs executive order to overhaul pediatric vaccine recommendations
- Unapproved in US for decades, levosimendan stumbles in phase 3 as Tenax eyes narrow FDA path
- Jalapeño Recall Reaches Seven Grocery Chains In 26 States
- New Melanoma Drug, Tudriqev, Based On Herpes Virus Granted FDA Accelerated Approval
- Even Light Exercise May Lower Stroke Risk For People With A-fib
- Working At Home Makes Breastfeeding Harder, Not Easier, Study Says
- Kidney Dialysis: Here's What You Need To Know
- What 524B and QMSR Change About Medical Device Risk
- Taking Lean Manufacturing to the Next Level
- Why Few MedTech Sales Teams Are Using AI Where It Matters Most
- ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms
- Abbott casts telenovela star Gabriela Spanic to take the drama out of colon cancer screening
- Bristol Myers Squibb lays out plan for $2.3B manufacturing facility in Houston
- Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
- Zepbound Lowers Heart Attack, Stroke Risk Among Type 2 Diabetics
- Heart Problems Linked To Brain Shrinkage Among People With Genetic Risk For Alzheimer's
- Budget Battle Erupts In Nation's Capital Over Opioid Settlement Money
- Rising Global Heat Linked To Mental Health Risks In Children
- Quanterix hires GE Healthcare, Exact Sciences alum as chief commercial officer
- Why Organizations Miss Emerging Product Risk: Understanding the engineering mechanisms that remain hidden long before complaint trends become visible
- Update on the SEC’s Work Toward Treasury Clearing Implementation [August 2026]
- FDA Reverses Course, Approves First mRNA Flu Shot
- Therapy Dogs Aid Stroke Rehab
- Can Yoga Calm A Grumpy Gut?
- Review Finds Little Proof IVF Embryo Transfer Tricks Boost Success
- Short-Term Vegan Diet Linked To Lower Inflammation And Aging
- Medicaid Work Rule Leaves Homeless People In The Cold
- Wildfire Smoke An Increasing Hazard To U.S. Pregnancies, Study Says
- Salmonella Outbreak Linked To Imported Jalapeños Sickens Hundreds
- Leo Pharma readies rare disease education push for 2nd annual GPP awareness day
- Wildfire Smoke Sends More Oregonians To Emergency Rooms
- Peanut Allergy? Fecal Transplant Might Be A Solution, Pilot Trial Finds
- The Interface is the Risk: A MedTech Blueprint for AI and System Integration
- Restoring Regulatory Clarity: Statement on Technical Amendments to Rule 0‑1(a)(7)
- Beyond the Status Report: Using LLMs to Reveal the True State of SaMD Development
- Headstands and Summervaults: A Statement on Crypto Vaults and Lending Strategies
- Remarks at the Small Business Capital Formation Advisory Committee Meeting
- Seeking Public Comment on Seeking Public Capital: Remarks Before the Small Business Capital Formation Advisory Committee
Michigan healthcare freedom community forum
There is evidence that a significant percentage - about 10.9% - of women who abort using mifepristone experience medical side effects and injuries. FDA published data on this politically tinged drug show much lower adverse effect levels. U.S. Food and Drug Commissioner Marty Makary has promised a full and accurate review of this drug:
FDA Head Makary Commits To Releasing ‘Robust’ Abortion Pill Review As Soon As It Is Completed
By Jordan Boyd - December 10, 2025U.S. Food and Drug Commissioner Marty Makary confirmed on Wednesday that his agency’s review of the drug responsible for a majority of the nation’s abortions is underway and will be publicized as soon as results are finalized.
As stories of women suffering injuries and even death after taking abortion pills without medical supervision gained traction, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. pledged that the administration would “study the safety of mifepristone.” By March 2025, Makary also promised “to review the ongoing data.”
News of the review, however, remained sparse and vague for most of 2025, prompting Congress and pro-life organizations to pressure the FDA to roll back Biden-era expansions that make it easier for people to obtain mifepristone via mail or a drug store pharmacy without a doctor visit or medical oversight. Polling suggesting a majority of likely voters also want the FDA to protect women from the dangers of abortion pills, also made an appearance shortly after both Kennedy and Makary announced the FDA “is conducting its own review of the evidence.”
The FDA previously failed to respond to The Federalist’s questions about who is leading the review, what process the review will follow, whether it had formally commenced, and how long it is estimated to take. In his December 9 sitdown with the Daily Signal, however, Makary confirmed that the FDA’s mifepristone review is in the “data acquisition phase” and will continue “under my auspices.”
“It’ll be reported up to me,” he said,.
While Makary did not specify the review’s timeline or end date, he committed to publicizing the FDA’s findings as soon as they “are available.”
“We’re not going to decide what the results are before we’ve done the study,” he continued. “We’re doing the study the right way. And when you do the study the right way, and I’ve done dozens of these studies as a Johns Hopkins professor, you gotta do the studies in data the right way with the right pace.”
The Ethics and Public Policy Center’s April 2025 examination of private medical insurance data determined that more than one in 10 women who take mifepristone suffer a serious adverse event. This determined rate of life-threatening complications, such as hemorrhage and infection, after pill-induced abortion is at least 22 times higher than what the FDA and mifepristone manufacturer Danco Laboratories boast.
The FDA’s study, Makary announced, is even “bigger” and “more robust” than EPPC’s undertaking. While the EPPC study was the “largest known study of the abortion pill” at the time, Makary said “it didn’t have granularity into the patient characteristics in a way that many researchers would want to have” which is why the FDA plans to probe mifepristone with an expanded review.
Makary’s comments come shortly after Bloomberg published an anonymously-sourced article claiming the FDA head was “Slow Walking a Long-Awaited Abortion Pill Safety Study.” Pro-life group SBA List Pro-Life America used the article to call for Makary’s firing.
No review is required for the FDA to reinstate some of the common-sense abortion pill safeguards. In fact, an embrace of requirements such as an in-person doctor visit would bring the second Trump administration’s FDA up to speed with the parameters that were present during the first Trump administration. Until that happens, it is easier now than ever for anyone to obtain mifepristone regardless of state laws prohibiting it.
The majority of abortions, 70 percent, are already believed to be unwanted, coerced, or inconsistent with the mother’s values and desires. A rise in abortion pill poisoning anecdotes further confirms that abusers and other bad actors take advantage of the FDA’s currently relaxed mail-order abortion drug provisions to force mifepristone on pregnant women.
The FDA recently added more mifepristone options to the market by approving a generic version of the abortion pill. The FDA claimed to The Federalist that the HHS secretary was required “by law” to “approve an application if it demonstrates that the generic drug is identical to the brand-name drug.” The off-brand abortion pill, however, went unapproved for 1,207 days under the Biden administration and 253 days under Trump before the FDA greenlit it.
Jordan Boyd is an award-winning staff writer at The Federalist and producer of “The Federalist Radio Hour.” Her work has also been featured in The Daily Wire, Fox News, and RealClearPolitics. Jordan graduated from Baylor University where she majored in political science and minored in journalism. Follow her on X @jordanboydtx.
City wastewater treatment plants don't filter out mifepristone, so abortive mothers are probably not the only ones suffering side effects of this drug.
https://answersingenesis.org/sanctity-of-life/study-finds-abortion-drugs-in-us-drinking-water/
Study Finds Abortion Drugs in US Drinking Water
Ken Ham | August 4, 2026
Well, this is truly horrifying.
In 2025, 25 Republican lawmakers “signed a letter calling on the Trump administration to determine whether the abortion pill mifepristone has an environmental impact on the U.S. water system.”
Mifepristone is the first in a set of two drugs that end the life (are used to murder) of an unborn child, typically early in pregnancy (up to about 10 weeks gestational age). This drug is basically an antiprogestin, blocking the woman’s body from receiving the hormone progesterone that allows the uterine lining to accept the baby’s placenta. Unable to receive nourishment from mom due to the lack of progesterone, the baby dies and a second drug induces contractions to deliver the dead baby’s tiny body.
About 63% of abortions today are these chemical abortions (642,700 babies killed in 2023), and an increasing number take place at home. But what happens to the mifepristone after the woman takes it and kills her baby? The baby and the mifepristone leave the woman’s body and are flushed down the toilet to presumably be removed by the wastewater treatment plant—except no one was testing if conventional water treatment removed drugs like mifepristone from drinking water. Turns out, according to a new study, it doesn’t.
This study published in Issues in Law & Medicine found “a statistically significant amount of mifepristone was found in all but one of the nine water sources” that were tested (water came from Austin, TX; Blacksburg, VA; and Carbondale, IL). The study authors write:
"Conventional water treatment was not effective for removing this EDC [endocrine-disrupting compound] from water in all cities we tested. Two cities showed significant mean concentrations even in tap water."
What impact does this have on the health and fertility of the people drinking the water or the plants and animals that live in or around the water? No one knows because it’s never been studied! But the study summarizes what we do know about these kinds of compounds that disrupt the endocrine (hormone) system:
"Past research has shown that endocrine-disrupting compounds (EDCs), including steroid hormones, synthetic estrogens and progestins found in oral contraceptives, are present in water supplies. This problem remains an environmental and health concern, especially given the widespread use of contraceptives and the increased prevalence of medication abortion in recent years. These compounds have a number of deleterious effects on human and animal biology, particularly aquatic animals. Small amounts of these chemicals (parts per trillion) can affect the endocrine system of animals and humans. Progestins, including specifically the anti-progesterone synthetic steroid hormone mifepristone, have been found to have disruptive effects on the fertility and reproduction of fish. Moreover, further highlighting the potential for environmental toxicity and contamination, the FDA recommends treating any unused mifepristone pills as hazardous waste."
In other words, we don’t know the effect on human and environmental health yet for sure, but it’s probably not good!
According to an article reporting on this story:
“The EPA relied on studies that were done . . . in 1996 . . . to make sure that the excreted chemicals in the wastewater and the thrown away pills . . . would not reach a level that would hinder U.S. fertility rates,” [Vice chairman of the Committee on Health and Human Services in the Kansas House of Representatives Ron] Bryce said. “Since then . . . up to 63% or more of abortions are done by chemical abortions. Maybe—who knows—a million a year. And so the levels of mifepristone in our wastewater have grown dramatically.”
Infertility has skyrocketed . . . 84% between 1990 and 2021 globally. . . . The abortion pill was first approved in the U.S. in 2000 and approved in many European countries in the late 1980s and early ‘90s. In 2021, the study found that more than 110 million women faced infertility, and one in 10 women within the reproductive age range were infertile.
Bryce . . . is calling for a study to be done that analyzes infertility in light of mifepristone in the U.S. water system.
“[A] study that was done about a year ago on female frogs [found that] when they were exposed to mifepristone that is considered the level that is in our drinking water today, they had half as many babies,” he said. “And so we’re looking at fertility rates that are very low in the United States and in the Western civilization. . . . It’s either environmental factors or it’s behavioral factors. It’s probably a combination of the two. . . . We really need to get to the bottom of the environmental factors that might be contributing to this, and it’s just obvious that we need to look at the levels of mifepristone in our water.” [emphasis added]
Abortion harms everyone, babies first and foremost, but also men and women—even those not involved in any way with abortion.
Abortion advocates love to say that what a woman does with “her body” (but really, we’re talking about a woman’s body and a totally separate body, her unborn child, which is not part of her body but has his or her own DNA—a unique combination of information different to any other human being) is a medical decision between her and her doctor. But abortion doesn’t just impact a woman and her baby, who loses his or her life. This new study highlights yet another way abortion impacts everyone as millions of un-consenting Americans ingest harmful compounds that may wreak havoc on their own endocrine system and their future fertility (not to mention the environmental considerations that also impact everyone in one way or another!).Abortion harms everyone, babies first and foremost, but also men and women—even those not involved in any way with abortion. This new study is just another example of the consequences of a culture that has abandoned God’s Word as the foundation for morality and has legalized and commercialized the slaughter of the unborn.
Oh, and it’s a good reminder to filter your tap water! The study suggests, “Maximum removal requires tertiary treatment, such as membrane bioreactors [like a reverse osmosis system], oxidation, or ozonation.”
Thanks for stopping by and thanks for praying,
Ken
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.























